Clonal evolution in myelodysplastic syndromes

[1]  H. Kantarjian,et al.  Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring , 2018, American journal of hematology.

[2]  A. Trumpp,et al.  Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. , 2016, Blood.

[3]  E. van den Berg,et al.  Guidelines for genomic array analysis in acquired haematological neoplastic disorders , 2016, Genes, chromosomes & cancer.

[4]  M. Stratton,et al.  Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents , 2016, Nature Communications.

[5]  Christopher A. Miller,et al.  Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. , 2016, Blood.

[6]  A. Stamatoullas,et al.  Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. , 2016, Blood.

[7]  H. Kantarjian,et al.  Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring , 2016, American journal of hematology.

[8]  G. Mufti,et al.  SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment , 2015, Nature Communications.

[9]  M. Konopleva,et al.  Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. , 2015, Leukemia research.

[10]  T. Haferlach,et al.  Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia , 2015, Haematologica.

[11]  A. Baruchel,et al.  Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network , 2015, Nature Genetics.

[12]  D. Longo,et al.  Improving Prospects for Targeting RAS. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Hernández‐Rivas,et al.  Cryofibrinogenaemia in a patient with multiple myeloma and necrotizing vasculitis , 2015, British journal of haematology.

[14]  M. Calasanz,et al.  CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q) , 2015, British journal of haematology.

[15]  S. Carr,et al.  Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS , 2015, Nature.

[16]  G. Mufti,et al.  High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS) , 2015, Leukemia.

[17]  G. Mufti,et al.  CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis. , 2015, The Lancet. Haematology.

[18]  K. Döhner,et al.  Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q , 2015, Leukemia.

[19]  N. McGranahan,et al.  Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. , 2015, Cancer cell.

[20]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[21]  S. Gabriel,et al.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.

[22]  O. Abdel-Wahab,et al.  Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. , 2014, Blood.

[23]  G. Vassiliou,et al.  Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer? , 2014, Disease Models & Mechanisms.

[24]  S. Linnarsson,et al.  Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. , 2014, Cancer cell.

[25]  M. Cazzola,et al.  From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. , 2014, Blood.

[26]  G. Mufti,et al.  p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q) , 2014, Haematologica.

[27]  K. Sailaja,et al.  NRAS mutations in de novo acute leukemia: prevalence and clinical significance. , 2014, Indian journal of biochemistry & biophysics.

[28]  Thomas J. Hudson,et al.  Corrigendum: Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia , 2014, Nature.

[29]  Christopher A. Miller,et al.  Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. , 2014, Cancer cell.

[30]  S. Miyano,et al.  Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations , 2014, Haematologica.

[31]  C Haferlach,et al.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.

[32]  O. Abdel-Wahab,et al.  Frequent ASXL 2 mutations in acute myeloid leukemia patients with t ( 8 ; 21 ) / RUNX 1-RUNX 1 T 1 chromosomal translocations , 2014 .

[33]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[34]  Z. Estrov,et al.  Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML , 2013, Leukemia.

[35]  S. Miyano,et al.  Somatic SETBP1 mutations in myeloid malignancies , 2013, Nature Genetics.

[36]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[37]  E Mardis,et al.  Clonal diversity of recurrently mutated genes in myelodysplastic syndromes , 2013, Leukemia.

[38]  I. Weissman,et al.  Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes , 2013, Proceedings of the National Academy of Sciences.

[39]  Joshua F. McMichael,et al.  The Origin and Evolution of Mutations in Acute Myeloid Leukemia , 2012, Cell.

[40]  Ken Chen,et al.  Clonal architecture of secondary acute myeloid leukemia. , 2012, The New England journal of medicine.

[41]  E. van den Berg,et al.  Microarray‐based genomic profiling as a diagnostic tool in acute lymphoblastic leukemia , 2011, Genes, chromosomes & cancer.

[42]  S. Sugano,et al.  Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[43]  D. Neuberg,et al.  Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[44]  Eva Hellström-Lindberg,et al.  TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Stefan Heinrichs,et al.  SNP array analysis in hematologic malignancies: avoiding false discoveries. , 2010, Blood.

[46]  L. Shaffer,et al.  Comprar ISCN 2009 - An International System for Human Cytogenetic Nomenclature | Marilyn L. Slovak | 9783805589857 | Karger AG , 2009 .

[47]  M. E. Duncan,et al.  Prevalence and clinical significance , 2005 .

[48]  R. Gale,et al.  Chronic myeloid leukemia. , 1992, The American journal of medicine.